Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 1,034 shares of the company's stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $10.00, for a total value of $10,340.00. Following the completion of the sale, the chief financial officer now owns 100,783 shares in the company, valued at $1,007,830. This trade represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dominic Piscitelli also recently made the following trade(s):

• On Tuesday, June 24th, Dominic Piscitelli sold 32,466 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.50, for a total transaction of $340,893.00.
• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Wednesday, June 11th, Dominic Piscitelli sold 2,976 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.01, for a total value of $29,789.76.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total value of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $26,026.00.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC traded down $0.16 during midday trading on Friday, reaching $10.35. The company's stock had a trading volume of 607,696 shares, compared to its average volume of 793,145. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The firm has a 50 day moving average price of $7.05 and a two-hundred day moving average price of $7.70. The firm has a market capitalization of $881.60 million, a price-to-earnings ratio of -5.53 and a beta of 1.49.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, research analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ORIC. Wedbush reissued an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a research report on Monday. Oppenheimer cut their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $19.17.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ORIC. Jane Street Group LLC boosted its position in shares of Oric Pharmaceuticals by 56.0% during the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock valued at $174,000 after acquiring an additional 11,198 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Oric Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock worth $2,841,000 after buying an additional 473,600 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Oric Pharmaceuticals by 9.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock worth $1,645,000 after buying an additional 24,778 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of Oric Pharmaceuticals during the 1st quarter valued at $1,133,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after buying an additional 3,131 shares in the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.